WO2012067269A1

WO2012067269A1 - Aminoalkoxyphenyl compounds and their use in the treatment of disease

Info

Publication number: WO2012067269A1
Application number: PCT/JP2011/077275
Authority: WO
Inventors: Seiji Hori; Thomas Mcinally; Daisuke Urabe
Original assignee: Dainippon Sumitomo Pharma Co., Ltd.; Astrazeneca Aktiebolag
Priority date: 2010-11-19
Filing date: 2011-11-18
Publication date: 2012-05-24

Abstract

The invention concerns compounds of Formula (I): (I) wherein n, m, p, R¹ and R² are as defined in the description. The present invention also relates to processes for the preparation of such compounds, novel intermediates useful in the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of disease, for example cancer.

Description

DESCRIPTIO

AMINO ALKOXYPHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE

Field of the Invention

The present invention relates to novel aminoalkoxyphenyl compounds and, more particularly, to novel aminoalkoxyphenyl compounds that act as TLR7 agonists. This invention also relates to methods for the preparation of such compounds and novel

intermediates in the preparation thereof, to pharmaceutical compositions containing such compounds, to the use of such compounds in the preparation of medicaments, and to the use of such compounds in the treatment of conditions mediated by TLR7, such as allergic diseases, autoimmune diseases, viral diseases and, in particular, cancer.

Background of the Invention

Toll-like receptors (TLRs) are expressed on a variety of immune cells, including macrophages and dendritic cells (DCs). TLRs recognise molecular motifs on pathogens called pathogen-associated molecular patterns (PAMPs). To date, 13 TLRs have been identified in man, these include TLRs 1, 2, 4, 5 and 6, which are confined to the cell surface and TLRs 3, 7, 8 and 9 which are expressed in endosomes. Different TLRs recognise different pathogen- derived ligands, for example TLRs 2 (bacterial lipoproteins), 3 (double-stranded RNA/poly (I:C)), 4 (lipopolysaccharides), 5 (flagellin), 7 (single-stranded RNA) and 9 (CpG-containing DNA). Ligation of TLRs on antigen-presenting cells, such as DCs, leads to production of proinflammatory cytokines, DC maturation and priming of the adaptive immune system.

TLR7 and TLR9 are expressed by plasmacytoid dendritic cells (pDCs) and ligand recognition leads to the secretion of interferon-a (INF-a). Preclinical studies investigating the effects of activation of TLRs, using bacterial or viral components, dosed as monotherapy and/or combined with anti-tumor agents, have shown tumour growth inhibition in a variety of murine tumour models.

Several small molecule TLR7 agonists have been described, including the

imidazoquinoline, imiquimod, which has been used to treat a number of dermatological conditions e.g. genital warts, molluscum contagiosum and melanoma. In the case of melanoma, topically applied imiquimod (Aldara™, Graceway Pharmaceuticals, Bristol, TN) demonstrated therapeutic responses in cutaneous metastatic melanoma and lentigo maligna and has been approved for the treatment of superficial basal cell carcinoma (BCC). Preclinical and clinical studies indicate that imiquimod is likely to function through the induction of type 1 IFN and IFN-inducible genes, which in turn can have direct effects on tumour cell growth and/or harness components of the adaptive immune system. 852A is another imidazoquinoline, which unlike imiquimod, is suitable for systemic administration. Currently 852A is in phase II clinical trials in a number of cancer indications, including melanoma.

Nevertheless, there remains a need for further TLR7 agonists which are more effective in the treatment of disease, for example cancer, by reason of their superior potency and/or advantageous physical properties (for example, higher permeability, and/or lower plasma protein binding) and/or favourable toxicity profiles and/or favourable metabolic profiles in comparison with other known TLR7 agonists, for example 852A. Summary of the Invention

As now demonstrated herein, the arninoalkoxyphenyl compounds of the present invention are capable of activating TLR7 in vitro. As a consequence of this activity, the arninoalkoxyphenyl compounds of the present invention are expected to have value in the prevention or treatment of human disease, for example cancer, either as a monotherapy or in combination with other chemotherapeutic agents or radiotherapy regimens.

As a further feature of the invention, compounds of the invention have surprisingly advantageous selectivity for TLR7 over TLR8. TLR7 and TLR8 differ in their cellular expression and as a result stimulation with selective agonists induces different cytokine profiles. TLR8 stimulation (either as a TLR8 selective agonist or a TLR7/8 dual agonist) results in enhanced levels of pro-inflammatory cytokines including TNFa, IL-Ιβ and IL-6 (Gorden et al (2005) J. Immunol. 174, 1259-1268). Conversely, TLR8 stimulation results in lower levels of IFNa. Therefore, a TLR7 selective agonist would favour induction of IFNa, which is important in suppression of Th2 cytokines (Huber et al (2010) J. Immunol. 185; 813- 817) that are elevated in allergic disease. In addition, by making compounds selective for TLR7 compared to TLR8 the induction of proinflammatory cytokines would be reduced thus avoiding inflammatory responses in man.

As a further feature of the invention, compounds of the invention also have a surprisingly advantageous hERG profile. Compounds that have significant activities against the hERG ion channel are relevant to inducing QT prolongation and are disfavored because such activity is implicated in the development of Torsades de Pointes and cardiac death.

According to a first aspect of the present invention, there is therefore provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof:

(I)

wherein:

n is 1, 2 or 3;

m is 1 or 2;

p is 1 or 2;

1 "2

R is Ci_-4alkyl or hydroxy C_2-4alkyl and R is hydrogen or C_1-4alkyl;>

or R¹ and R² together with the nitrogen to which they are attached form piperazin- 1 -yl optionally substituted on the available nitrogen by C_1-3alkyl, or pyrrolidin-l-yl.

For the avoidance of doubt, the "available nitrogen" of a piperazin- 1-yl is at the 4 position of the piperazin- 1-yl.

It is to be understood that, insofar as certain of the compounds of Formula (I) defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses the above-mentioned activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

It is to be understood that certain compounds of Formula (I) above may exist in unsolvated forms as well as solvated forms, such as, for example, hydrated forms. It is to be understood that the present invention encompasses all such solvated forms that activate TLR7.

It is also to be understood that certain compounds of the Formula (I) may exist in crystalline form and exhibit polymorphism. The present invention encompasses all such forms that activate TLR7.

The term "C_1-4alkyl" is intended to mean a saturated carbon chain of 1 to 4 carbon atoms in length which may be straight chained or branched. However references to individual alkyl groups such as "propyl" are specific for the straight chain version only and references to individual branched chain alkyl groups such as tert-butyl are specific for the branched chain version only. For example, "C_1-4alkyl" includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl. The term "C_2-4alkyl" and "C_1-3alkyl" are to be construed accordingly.

The term "hydroxyC_2-4alkyl" is intended to mean a saturated carbon chain of 2 to 4 carbon atoms in length, which may be straight-chained or branched, wherein one of the hydrogen atoms has been replaced by a hydroxy group. For example "hydroxyC_2-4alkyl" includes, but is not limited to, hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1- hydroxyisopropyl and 4-hydroxybutyl.

In one embodiment there is rovided a compound of Formula (I) of Formula (IA):

1 2

or a pharmaceutically acceptable salt thereof, wherein the values of R , R and m, p and n may take any of the values defined herein for R , R and m, p and n respectively.

The variable groups R , R and m, p and n may also take the values as indicated below. Such values may be used together with any of the definitions, claims, aspects or embodiments defined herein to provide further embodiments or claims of the invention, and unless the context does not permit, any number of said variable group definitions may be used in any combination with each other to form further embodiments, aspects and claims. For example, the skilled person would understand that paragraphs (3), (6), (8) and (10) could be combined to provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein p represents 1 , m and n represent 2, R¹ represents methyl or 2-hydroxyethyl, and R² represents hydrogen. Or, for example, the skilled person would understand that paragraphs (3), (6) and (15) could be combined to provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein p represents 1, m and n represent 2, R¹ and R²combined with the nitrogen to which they are attached form piperazin-l-yl.

(1) m=l; p= =1.

(2) m=l; p= =2.

(3) m=2; p= =1.

(4) m=2; p= =2. (5) n=l .

(6) n=2.

(7) n=3.

(8) R¹ represents methyl or 2 -hydroxy ethyl.

(9) R² represents hydrogen or methyl.

(10) R represents hydrogen.

(1 1) R¹ represents methyl and R² represents hydrogen.

(12) R¹ and R² both represent methyl.

(13) R¹ represents 2 -hydroxy ethyl and R² represents hydrogen.

1 2

(14) R and R together with the nitrogen to which they are attached form pyrroli din- 1- yl or piperazin-l -yl optionally substituted by C_1-3alkyl.

1 'J

(15) R and R combined with the nitrogen to which they are attached form piperazin-

1 -yl.

Particular novel compounds of Formula (I) include, but are not limited to, the following compounds:

(iS)-3 -(2- Amino-5 - {4- [3 -(2-hydroxyethylamino)propoxy] -2-methoxybenzyl } -6- methylpyrimidin-4-ylamino)hexan- l-ol;

(5)-3-(2-Amino-5-{2-methoxy-4-[3-(methylamino)propoxy]benzyl}-6- methylpyrimidin-4-ylamino)hexan- l -ol;

(S)-3-(2-Amino-5-{2-methoxy-4-[3-(piperazin-l -yl)propoxy]benzyl}-6- methylpyrimidin-4-ylamino)hexan- l-ol;

(S)-3-(2-Amino-5-{4-[3-(dimethylamino)propoxy]-2-methoxybenzyl}-6- methylpyrimidin-4-ylamino)hexan- 1 -ol;

(5)-2-(2-Amino-5 - {4- [3 -(dimethylamino)propoxy] -2-methoxybenzyl } -6- methylpyrimidin-4-ylamino)pentan- 1 -ol;

(S)-2-(2- Amino-5 - { 2-methoxy-4- [3 -(methylamino)propoxy]benzyl } -6- methylpyrimidin-4-ylamino)pentan- 1 -ol;

(S)-2-(2- Amino-5- { 4- [3 -(2-hydroxyethylamino)propoxy] -2-methoxybenzyl } -6- methylpyrimidin-4-ylamino)pentan- 1 -ol;

(S)-2-(2-Amino-5-{2-methoxy-4-[3-(piperazin-l-yl)propoxy]benzyl}-6- methylpyrimidin-4-ylamino)pentan-l-ol; and

(3iS)-3 - [(2 -Amino-5 - {4- [2-(dimethylamino)ethoxy] -2-methoxybenzyl } -6- methylpyrimidin-4-yl)amino]hexan- 1 -ol;

and pharmaceutically acceptable salts thereof. In one embodiment of the invention there is provided any Example described herein, or a pharmaceutically acceptable salt thereof.

A suitable pharmaceutically-acceptable salt of a compound of the Formula (I) is, for example, an acid-addition salt of a compound of the Formula (I), for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, trifluoroacetic, citric or maleic acid.

The compounds of the invention may be administered in the form of a pro-drug, that is a compound that is broken down in the human or animal body to release a compound of the invention. A pro-drug may be used to alter the physical properties and/or the pharmacokinetic properties of a compound of the invention. A pro-drug can be formed when the compound of the invention contains a suitable group or substituent to which a property-modifying group can be attached. Examples of pro-drugs include in-vivo cleavable amide derivatives that may be formed at an amino group in a compound of the Formula (I).

Accordingly, the present invention includes those compounds of the Formula (I) as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the Formula (I) that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the Formula (I) may be a synthetically-produced compound or a metabolically-produced compound.

A suitable pharmaceutically-acceptable pro-drug of a compound of the Formula (I) is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.

Various forms of pro-drug have been described, for example in the following documents:

a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et at. (Academic Press, 1985);

b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985);

c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Pro-drugs", by H. Bundgaard p. 113- 191 (1991);

d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);

e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al, Chem. Pharm. Bull.. 32, 692 (1984);

g) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", A.C.S. Symposium Series, Volume 14; and

h) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.

A suitable pharmaceutically-acceptable pro-drug of a compound of the Formula (I) that possesses an amino group is, for example, an in-vivo cleavable amide derivative thereof. Suitable pharmaceutically-acceptable amides from an amino group include, for example an amide formed with C_1-10alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the

phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N V- dialkylaminomethyl, morpholinomethyl, piperazin-l-ylmethyl and 4-(C_1-4alkyl)piperazin-l- ylmethyl.

The in-vivo effects of a compound of the Formula (I) may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the Formula (I). As stated hereinbefore, the in-vivo effects of a compound of the Formula (I) may also be exerted by way of metabolism of a precursor compound (a prodrug).

Preparation of Compounds of Formula (Γ)

Compounds of Formula (I) may be prepared as described in the following reaction Schemes.

Step (T)

Scheme 1

A compound of Formula (IV) can be prepared by reaction of a compound of Formula (III) with a compound of Formula (II) wherein PG¹ represents a suitable protecting group, for example a tert-butyldimethylsilyl group, as shown in Scheme 1. The reaction may be carried - out in the presence of acetic acid and piperidine in a suitable solvent, such as toluene, and at a suitable temperature, for example 50-150°C. Step (ip

Scheme 2

A compound of Formula (V) can be prepared by reduction of a compound of Formula (IV), as shown in Scheme 2. The reaction may be carried out with a catalyst such as Pd/C under an atmosphere of H₂ (1-20 bar) in a suitable solvent, such as MeOH, and at a suitable temperature, for example 20-100°C.

A compound of Formula (V) can be synthesized by alternative methods, shown in Scheme 3.

(VIII)

Scheme 3

Step iiif)

A compound of Formula (V) may be prepared by a Heck reaction between a compound of Formula (VI) and a compound of Formula (VII) as shown in Scheme 1 wherein Hal represents bromo or iodo. The reaction may be carried out using a palladium catalyst, such as Pd(OAc)₂, bis(tri-o-tolylphosphine)palladium(II) dichloride or l,l-bis(di-tert- butylphosphino)feirocenepalladium(II) choloride (Pd-1 18), a base such as NaHC0₃, triethylamine or dicyclohexylmethylamine, and tetrabutylammonium chloride or bromide. The reaction is performed in a suitable solvent, such as THF, DMF or DMA, and at a suitable temperature, for example 50-150°C.

Step (iv) Alternatively a compound of Formula (V) may be prepared by reacting a compound of Formula (IX) with a base, such as NaH, in a suitable solvent, such as THF or DMF, at a suitable temperature, for example 0°C to r.t., followed by addition of a compound of Formula (VIII) wherein LG¹ represents a suitable leaving group, for example bromo or chloro. The reaction is then preferably heated, for example 50-100 °C, optionally in the presence of an additive such as KI.

Step (v

Scheme 4

A compound of Formula (X) may be prepared by reacting a compound of Formula (V) with guanidine or guanidine carbonate in a suitable solvent, such, as MeOH or EtOH, and at a suitable temperature, for example 50-150 °C.

Step (VP

Scheme 5

A compound of Formula (XI) may be prepared by reacting a compound of Formula (X) with POCl₃, at a suitable temperature, for example 50-100°C, when LG² represents chloro. Alternatively, a compound of Formula (XI) may be prepared by reacting a compound of Formula (X) with a sulfonyl chloride of formula R S0₂C1, wherein R represents C_1-3alkyl or optionally substituted aryl such as phenyl, 4-methylphenyl or 2,4,^'6-trimethylphenyl. The reaction may be carried out in a suitable solvent, such as DCM or THF, in the presence of a suitable base, such as N,N V',iV'-tetramethyl-l,3-propanediamine or triethylamine, at a

2 3

suitable temperature, for example 0-50°C, when LG represents -OS0₂ R .

Step (vifl

Scheme 6

A compound of Formula (XIII) may be prepared by reacting a compound of Formula (XI) with an excess of amine of Formula (XII) wherein PG² represents a suitable protecting group which can not be removed in a deprotection condition for PG¹, for example benzyl group, in a suitable, solvent, such as butanol, propionitrile, butyl acetate or 1 ,4-dioxane, and at a suitable temperature, for example 50-150°C, optionally in the presence of an additive such as trifluoroacetic acid or N,N-diisopropylethylamine. Alternatively, the reaction may be performed in a microwave at a suitable temperature, for example 50-200°C.

Alternatively, a compound of Formula (XIII) may be prepared by reacting a compound of Formula (XI) with a compound of Formula (XII-2):

(XI 1-2) followed by a step of protecting the hydroxyl group.

Step (viii)

Scheme 7

A compound of Formula (XIV) may be prepared by reacting a compound of Formula (XIII) with a de-protective agent for the protective group: PG¹. For example, a compound of Formula (XIV) may be prepared by reacting a compound of Formula (XIII) with

hydrochloric acid or trifluoroacetic acid in a suitable solvent, such as MeOH, and at a suitable temperature, for example 0-50 °C, when PG¹ is a group removable under acidic conditions.

Step (ix

Scheme 8

A compound of Formula (XV) may be prepared by reacting a compound of Formula (XIV) with an alkyl sulphonyl chloride of Formula R⁴S0₂C1, wherein R⁴ represents a d. ₃alkyl, in a suitable solvent, such as DCM or THF, in the presence of a suitable base, such as triethylamine, at a suitable temperature, for example 0-50 °C, wherein LG³ represents -OS0₂ R⁴.

Step(x

Scheme 9

A compound of Formula (XVI) may be prepared by reacting a compound of Formula

(XV) with an excess of amine of formula HNR R^', wherein R and R^" are the same as in the Formula (I), in a suitable solvent, such as DMF, acetonitrile or water, and at a suitable temperature, for example 50-150°C, optionally in the presence of an additive such as triethylamine or N,N-diisopropylethylamine. Alternatively, the reaction may be performed in a microwave at a suitable temperature, for example 50-200°C.

Step (xf)

Scheme 10

A compound of Formula (I) may be prepared by de-protection of a compound of Formula (XVI). When, PG² represents benzyl, the reaction may be carried out with a catalyst such as Pd/C under an atmosphere of H₂ (1 -20 bar) in a suitable solvent, such as MeOH, and at a suitable temperature, for example 20-100°C, optionally in the presence of an additive such as hydrochloric acid or acetic acid.

Alternatively, reaction of a compound of Formula (XVII) with a compound of Formula (XVIII) may give a compound of Formula (I), as shown in Scheme 1 1.

Scheme 11

A compound of Formula (XVII) may be prepared by the method described in Scheme 13 Step (i) to Step (vi), wherein an appropriate protective group "PG²" may be introduced in Step (v) in Scheme 13. For example, PG² may be a tri(Ci_4alkyl)silyl group (such as TBDMS or TMS).

Compounds of Formula (I) may be prepared by reacting a compound of a Formula (XVII) with a compound of Formula (XVIII), in the presence of suitable base (such as

CS2CO3), in a suitable solvent (such as DMF or NMP), optionally in the presence of Nal and at a suitable temperature such as 50-150°C, and the subsequent deprotection of PG² by the method described in Scheme 13 Step (viii).

An intermediate of Formula (XII) may be prepared by the Scheme 12:

Scheme 12

A compound of Formula (XX) is obtained by protecting the amino group of a compound of Formula (XIX) with protective group: PG³ such as terf-butoxycarbonyl. A compound of Formula (XXI) may be prepared by protecting the hydroxyl group of a compound of Formula (XX) with protective group: PG² such as benzyl. A compound of Formula (XII) may be prepared by de-protecting amino group. The reaction conditions used for each step are described in the examples in this specification.

Alternatively, the compound of Formula (I) may also be prepared as shown in Scheme

Scheme 13

The R^SA group may be a substituted or unsubstituted hydrocarbyl group. Conveniently R^5A may be a hydrocarbyl group selected from benzyl and Ci_-4alkyl, for example methyl or ethyl. LG⁴ represents halogen atom (such as chloro), or Ci_-3alkylsulfonyl (such as mesyl), or an optionally substituted arylsulfonyl (such as 2,4,6-triisopropylbenzenesulfonyl, 2,4,6- trimethylbenzenesulfonyl or -toluenesulfonyl).

Step (i): Compounds of a Formula (XLIII) may be prepared by reacting compounds of Formula (XLI) and (XLII) in a suitable solvent such as DMF in the presence of Pd-1 18 (1 ,1 -bis(di- err-butylphosphino)-ferrocenepalladium(II) dichloride), tetrabuty lammonium chloride, hydrate and N-cyclohexyl-N^"-methylcyclo-hexanamine at a sutiable temperature, for example 100°C. LG⁵ is a leaving group, for example a chloro or bromo. PG⁵ is a suitable protecting group, for example a benzyl-based protecting group, for example benzyl.

Step (ii): Compounds of Formula (XLIV) may be prepared by reacting a compound of Formula (XLIII) with guanidine or guanidine carbonate, in a suitable solvent, such as MeOH or EtOH, and at a suitable temperature, for example 50-150°C. Step (iii): Compounds of Formula (XLV) may be prepared by reacting a compound of Formula (XLIV) with POCI3, at a suitable temperature, for example 50-1 10°C.

Step (iv): Compounds of Formula (XL VI) may be prepared by reacting a compound of Formula (XLV) with an excess of the appropriate amine, in a suitable solvent, such as propionitrile, butanol or 1 ,4-dioxane, in the presence of TFA at a suitable temperature, for example 50-150°C. Alternatively, the reaction may be performed in a microwave at a suitable temperature, for example 50-200°C.

Step (v): Compounds of Formula (XL VII) may be prepared by reacting a compound of Formula (XL VI) with a suitable protecting group. For example PG⁶ may be a tri(Ci.

4alkyl)silyl group, for example TBDMS or TMS. In the case where PG⁶ is a silicon based protecting group, it may be added using, for example TBDMSC1, or TMSC1, in the presence of a suitable base, for example imidazole, in a suitable solvent such as DMF.

Step (vi): Compounds of Formula (XLVIII) may be prepared by using standard deprotection conditions that are known to be suitable for removing a PG⁵ group. For example, when PG⁵ is benzyl, this could involve stirring compounds of a Formula (XL VII) in a suitable solvent such as ethanol or EtOAc in the presence of H₂ and palladium on carbon.

Step (vii): Compounds of Formula (XLIX) may be prepared by reacting a compound of a Formula (XLVIII) with the appropriate amino alcohol, in a suitable solvent such as THF using Mitsunobu conditions, for example using diisopropyl azodicarboxylate and

triphenylphosphine.

Step (viii): Compounds of Formula (I) may be prepared by using appropriate deprotection conditions known to be suitable for removing the PG⁶ group. For example, if PG⁶ were a silicon-based protecting group such as TBDMS, then the deprotection could involve reaction of a compound of Formula (XLIX) with a fluoride salt, for example tetra-n- butylammonium fluoride (TBAF), in a suitable solvent such as CH₂C1₂. Alternatively, such a deproection may be performed using SCX resin (strong cation exchange resin) with a suitable solvent such as acetonitrile.

The compounds described herein in the Schemes and associated text, and later in the detailed experimental section, are useful intermediates for the preparation of the compounds of Formula (I) and may be isolated as a free base or as a salt. Therefore, in further aspects and embodiments of the invention there is provided an intermediate described herein, or a salt thereof, wherein any of the variable groups described for said intermediate may take any of the values described herein in connection with that group. Compounds of Formula (XII) or (XII-2) have a chiral centre at the carbon atom. In further embodiments there is provided each of such intermediates, or a salt thereof, wherein the intermediate has the (^-stereochemical configuration as shown below.

(XII-2) Chiral (XII) Chiral Compounds of Formulae (II), (III), (VI), (VII), (IX), (XVIII) and (XIX) are known compounds or can be prepared from known compounds by conventional methods or their synthesis is described herein.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the reagents may need to be protected by protecting groups. Thus, the preparation of the compounds of

Formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.

The protection and deprotection of functional groups is described in 'Protective

Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and

'Protective Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley- Interscience (1999).

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically- acceptable diluent or carrier. The pharmaceutical composition may be used in the treatment of cancer. The composition may be in a form suitable for oral administration, for example as a tablet or capsule; for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion; for topical

administration as an ointment or cream; or for rectal administration as a suppository.

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, could also be administered as an air spray for inhalation. The air spray (e.g., spray, aerosol, dry powder preparation, etc.) could be optionally formulated as an aqueous solution or suspension, or as an aerosol delivered from a pressurized pack such as a pressurised metered dose inhaler by using, for example, a liquefied propellant. A dry powder preparation may also be used. An aerosol appropriate for inhalation may be either a suspension or solution, and would typically contain the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and any appropriate propellants such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or a mixture thereof. Specifically, it may contain hydrofluoroalkane, particularly 1 , 1,1 ,2- tetrafluoroethane, heptafluoroalkane (HFA) such as 1 ,1 ,1 ,2,3,3,3-heptafluoro-n-propane, or a mixture thereof. An aerosol may optionally contain an additional preparation excipient well- known to those skilled in the art such as surfactant (e.g., oleic acid or lecithin) and cosolvent (e.g., ethanol), etc. Specifically, an aerosol preparation could be delivered using the inhaler known as "Turbuhaler™".

For oral administration the compound of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide. Alternatively, the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.

For the preparation of soft gelatine capsules, the compound of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets. Also liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.

Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid

preparations may contain colouring agents, flavouring agents, saccharine and/or

carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.

The compound of Formula (I) will normally be administered to a warm blooded animal at a unit dose within the range 5-5000 mg/m² body area of the animal, i.e.

approximately 0.1-100 mg/kg, and this normally provides a therapeutically effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1 -250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansen; Chairman of Editorial Board), Pergamon Press 1990.

In the context of the present specification, the term "therapy" also includes

"prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

As used herein, the term "treatment" is intended to have its normal everyday meaning of dealing with a disease in order to entirely or partially relieve one, some or all of its symptoms, or to correct or compensate for the underlying pathology.

As used herein, the term "prophylaxis" is intended to have its normal everyday meaning and includes primary prophylaxis to prevent the development of the disease and secondary prophylaxis whereby the disease has already developed and the patient is temporarily or permanently protected against exacerbation or worsening of the disease or the development of new symptoms associated with the disease.

The compounds defined in the present invention are effective activators of TLR7 in vitro. Accordingly, the compounds of the present invention are expected to be potentially useful agents in the treatment of diseases or medical conditions mediated alone or in part by TLR7. For example, the following diseases and conditions listed in paragraphs 1 to 8 below may be treatable with compounds of the present invention.

1. respiratory tract: obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases;

hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus;

2. skin: psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid,

epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions;

3. eyes: blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral , fungal, and bacterial;

4. genitourinary: nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-vaginitis; Peyronie's disease; erectile dysfunction (both male and female);

5. allograft rejection: acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;

6. other auto-immune and allergic disorders including rheumatoid arthritis, irritable bowel syndrome, systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE syndrome, antiphospholipid syndrome and Sazary syndrome;

7. oncology: treatment of common cancers including bladder, head and neck, prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,

8. infectious diseases: virus diseases such as genital warts, common warts, plantar warts, hepatitis B, hepatitis C, herpes simplex virus, molluscum contagiosum, variola, human immunodeficiency virus (HIV), human papilloma virus (HPV), cytomegalovirus (CMV), varicella zoster virus (VZV), rhinovirus, adenovirus, coronavirus, influenza, para-influenza; bacterial diseases such as tuberculosis and mycobacterium avium, leprosy; other infectious diseases, such as fungal diseases, chlamydia, Candida, aspergillus, cryptococcal meningitis, Pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection and leishmaniasis.

It is envisaged that for the methods of treatment mentioned herein, the compound of Formula (I) will be administered to a mammal, more particularly a human being. Similarly, for the uses of a compound of Formula (I) for the treatment of diseases or medical conditions mentioned herein, it is envisaged that the compound of Formula (I) will be administered to a mammal, more particularly a human being.

According to a another aspect of the invention, there is therefore provided a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for use as a medicament.

According to a further aspect of the invention, there is provided a compound of

Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof for use in the treatment of a disease mediated through TLR7. In one embodiment of the invention, said disease mediated through TLR7 is cancer. In a further embodiment of the invention, said cancer is selected from bladder cancer, head and neck cancer, prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and

lymphoproliferative tumors. In one embodiment of the invention, said disease mediated through TLR7 is asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

According to a further aspect of the invention, there is provided the use of a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of a disease mediated through TLR7. In one embodiment of the invention, said disease mediated through TLR7 is cancer. In a further embodiment of the invention, said cancer is selected from bladder cancer, head and neck cancer, prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and lymphoproliferative tumors. In one embodiment of the invention, said disease mediated through TLR7 is asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

According to a further aspect of the invention, there is provided the use of a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of cancer. In one embodiment of the invention, said cancer is selected from bladder cancer, head and neck cancer, prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and lymphoproliferative tumors.

According to a further aspect of the invention, there is provided the use of a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

In one aspect of the invention there is provided a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.

According to a further aspect of the invention, there is provided a method of using a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for the treatment of cancer. Accordingly there is therefore provided a method of treating cancer in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined herein. In one embodiment of the invention, said cancer is selected from bladder cancer, head and neck cancer, prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and lymphoproliferative tumors.

According to a further aspect of the invention, there is provided a method of using a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

According to a further aspect of the invention, there is provided a method of treating a human suffering from a disease in which activation of TLR7 is beneficial, comprising the steps of administering to a person in need thereof of a therapeutically effective amount of a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof. In one embodiment of the invention, the disease in which activation of TLR7 is beneficial is cancer. In a further embodiment of the invention, said cancer is selected from bladder cancer, head and neck cancer, prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and lymphoproliferative tumors. In one embodiment of the invention, the disease in which activation of TLR7 is beneficial is asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

In any aspect or embodiment described herein the cancer may be bladder cancer.

In any aspect or embodiment described herein the cancer may be head and neck cancer.

In any aspect or embodiment described herein the cancer may be prostate cancer.

In any aspect or embodiment described herein the cancer may be breast cancer.

In any aspect or embodiment described herein the cancer may be lung cancer.

In any aspect or embodiment described herein the cancer may be uterus cancer.

In any aspect or embodiment described herein the cancer may be pancreatic cancer.

In any aspect or embodiment described herein the cancer may be liver cancer.

In any aspect or embodiment described herein the cancer may be renal cancer.

In any aspect or embodiment described herein the cancer may be ovarian cancer.

In any aspect or embodiment described herein the cancer may be colon cancer.

In any aspect or embodiment described herein the cancer may be stomach cancer.

In any aspect or embodiment described herein the cancer may be skin cancer.

In any aspect or embodiment described herein the cancer may be cerebral tumor.

In any aspect or embodiment described herein the cancer may be malignant myeloma cancer.

In any aspect or embodiment described herein the cancer may be lymphoproliferative tumors.

The anti cancer treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:-

(i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis platin, oxaliplatin, miriplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, amrubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and polokinase inhibitors); and topoisomerase inhibitors (for example

epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as finasteride;

(iii) anti-invasion agents [for example c-Src kinase family inhibitors like 4-(6-chloro-2,3- methylenedioxyanilino)-7-[2-(4-methylpiperazin-l-yl)ethoxy]-5-tetrahydropyran-4- yloxyquinazoline (AZD0530; International Patent Application WO 01/94341), N-(2-chloro-6- methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-l -yl]-2-methylpyrimidin-4- ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem., 2004, 47, 6658- 6661) and bosutinib (SKI-606), and metalloproteinase inhibitors like marimastat, inhibitors of urokinase plasminogen activator receptor function or antibodies to Heparanase];

(iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [Herceptin™], the anti-EGFR antibody panitumumab, the anti-erbB l antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibodies disclosed by Stern et al. Critical reviews in oncology/haematology, 2005, Vol. 54, ppl 1-29); such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as

JV-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-mo holinopropoxy)quinazoli -4-amine

(gefitinib, ZD 1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3- morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; inhibitors of the platelet-derived growth factor family such as imatinib and/or nilotinib (AMN107); inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib (BAY 43-9006), tipifarnib (Rl 15777) and lonafarnib (SCH66336)), inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; aurora kinase inhibitors (for example AZD1 152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 AND AX39459) , cyclin dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors and BRAF inhibitors such as Vemurafenib;

(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, [for example the anti vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and for example, a VEGF receptor tyrosine kinase inhibitor such as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU1 1248), axitinib (AG-013736), pazopanib (GW 786034) and 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin- 1 -ylpropoxy)quinazoline (AZD2171 ; Example 240 within WO 00/47212), compounds such as those disclosed in International Patent Applications W097/22596, WO 97/30035, WO 97/32856 and WO 98/13354 and compounds that work by other mechanisms (for example linomide, inhibitors of integrin ανβ3 function and angiostatin)];

(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669,

WO 01/92224, WO 02/04434 and WO 02/08213;

(vii) an endothelin receptor antagonist, for example zibotentan (ZD4054) or atrasentan;

(viii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;

(ix) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene directed enzyme pro drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

(x) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti idiotypic antibodies, approaches to decrease the function of immune suppressive cells such as regulatory T cells, myeloid-derived suppressor cells or IDO (indoleamine 2,3,-deoxygenase)-expressing dendritic cells, and approaches using cancer vaccines consisting of proteins or peptides derived from tumour-associated antigens such as NY-ESO-1 , MAGE-3, WT1 or Her2/neu.

According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the Formula (I) as defined hereinbefore and an additional anti tumour substance as defined hereinbefore for the conjoint treatment of cancer.

According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore, and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.

According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore, and an additional anti-tumour substance for the conjoint treatment of cancer.

According to this aspect of the invention there is provided a combination suitable for use in the treatment of cancer comprising a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof, and any one of the anti tumour agents listed under (i) - (ix) above.

Therefore in a further aspect of the invention there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) - (ix) herein above.

Herein, where the term "combination" is used it is to be understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention

"combination" refers to simultaneous administration. In another aspect of the invention "combination" refers to separate administration. In a further aspect of the invention

"combination" refers to sequential administration. Where the administration is sequential or separate, the delay in administering the second component should not be such as to lose the beneficial effect of the combination.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) - (ix) herein above, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) - (ix) herein above, in association with a pharmaceutically acceptable diluent or carrier for use in the treatment of cancer.

According to another feature of the invention there is provided the use of a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, in combination with an anti- tumour agent selected from one listed under (i) - (ix) herein above, in the manufacture of a medicament for use in cancer in a warm-blooded animal, such as man.

According to another feature of the invention there is provided a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) - (ix) herein above for use in the treatment of cancer in a warm-blooded animal, such as man.

Therefore in an additional feature of the invention, there is provided a method of treating cancer in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) - (ix) herein above.

According to a further aspect of the present invention there is provided a kit comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) - (ix) herein above.

According to a further aspect of the present invention there is provided a kit comprising:

a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in a first unit dosage form;

b) an anti-tumour agent selected from one listed under (i) - (ix) herein above; in a second unit dosage form; and

c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with an additional anti-tumour agent.

b) a second anti-tumour agent in a second unit dosage form; and c) container means for containing said first and second dosage forms.

In one aspect of the invention the compounds of Formula (I) may be useful as vaccine adjuvants.

As a further aspect of the invention there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined herein, for use as a vaccine adjuvant.

As a further aspect of the invention there is provided the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined herein, as a vaccine adjuvant, in the manufacture of a vaccine for the treatment of a disease or condition.

The invention still further provides a method of treating, or reducing the risk of, a disease or condition, which method comprises administering to a patient in need thereof a therapeutically effective amount of a vaccine and a compound of Formula (I), or a

pharmaceutically acceptable salt thereof, as defined herein.

The invention still further provides a method of increasing the response to a vaccine in a patient, which method comprises administering to a patient in need thereof a therapeutically effective amount of a vaccine and a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined herein.

Examples

The invention will now be illustrated with the following Examples in which generally, unless stated otherwise, all starting materials are commercially available, "r.t." means "room temperature", i.e. in the range 17 to 28°C, typically 20°C.

Electrospray ionization mass spectrometry (ESI mass) spectra were recorded using Waters Micromass ZQ™ mass spectrometer, Waters Waters 2790 Alliance™ separation module and Imtakt Cadenza CD-C 18™ columneluting with a gradient of A (MeCN) , B (H₂0) and C (2% formic acid/ 98% MeCN). 0.0-0.1 min: A 95%, B 2% and C 3%. 0.1-3.1 min: linear gradient from A 95%, B 2% and C 3% to A 1%, B 96% and C 3%. 3.1-3.5 min: A 1%, B 96% and C 3%.

Proton nuclear magnetic resonance (Ή NMR) spectra were recorded at 300-500MHz using deuterated chloroform, unless otherwise stated. The following abbreviations are used for NMR data: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, tt = triplet of triplets, br = broad, quintet = qn.

The following abbreviations may be used in this specification: EtOAc = ethyl acetate; DCM = dichloromethane; NMP = N-methylpyrrolidinone; DMF = N.iV-dimethylformamide; DMSO = dimethylsulfoxide; THF = tetrahydrofuran; MeOH= methanol; EtOH = ethanol; MeCN = acetonitrile; TFA = trifluoroacetic acid; TBDMS or TBS = tert-butyldimethylsilyl; TMS = trimethylsilyl; Boc = rr-butoxycarbonyl; Pd/C = palladium on carbon; DMAP = 4- dimethylaminopyridine; sat. = saturated; aq. = aqueous; DMA = N,N-dimethylacetamide; cone. = concentrated; h = hours; min(s) = mins.; M = molar; MS = mass spectrometry; ESI = electron spray ionisation method; m/z = mass to charge ratio; HPLC = high performance liquid chromatography; RPHPLC = reverse-phase high performance liquid chromatography; "T" = retention time (in minutes); DIPEA = diisopropylethylamine; SCX cartridge = strong cation exchange cartridge; FCC= flash column chromatography using silica.

Example 1: (S -3-(2-Amino-5-(4-[3-(2-hvdroxyethvIamino)propoxyl-2-methoxybenzvn- 6-methylpyrimidin-4-ylamino)hexan-l-ol

The title compound may be prepared by the steps described below:

The mixture of 4-hydroxy-2-methoxybenzaldehyde (10.0 g, 65.7 mmol), (3-bromopropoxy)- terr-butyldimethylsilane (25.0 g, 98.6 mmol) and K₂C0₃ (13.6 g, 98.6 mmol) in DMF (100 mL) was stirred at r.t. for 5h. The mixture was diluted with water and extracted with EtOAc. And the combined organic solutions were washed with water and brine, dried (Na₂S0₄), and concentrated. Purification by FCC, eluting with hexane / EtOAc gave 21.3 g of the sub-title compound as a yellow oil [as a mixture with (3-bromopropoxy)-tert-butyldimethylsilane]; LC-MS: m/z = 325 [MH⁺] (T = 2.68)

NaBH₄ (1.24 g, 32.8 mmol) was added to the solution of the product from step (i) (21.3 g) in THF (100 mL), MeOH (15 mL) and stirred at r.t. for 2.5h. The mixture was diluted with water and brine, and extracted with EtOAc. And the combined organic solutions were dried

(Na₂S0₄), and concentrated. Purification by FCC, eluting with hexane / EtOAc gave 18.5 g of the sub-title compound as a colourless oil (56.6 mmol, 86% overall); Ή NMR: 7.14 (1H, d), 6.42-6.48 (2H, m), 4.61 (2H, d), 4.06 (2H, t), 3.84 (3H, s), 3.80 (2H, t), 2.15 (1H, t), 1.94- 2.02 (2H, m), 0.89 (9H, s), 0.04 (6H, s); LC-MS: m/z = 309 [M-(OH)].

(iii) gr^-Butyli3- 4-(chloromethvn-3-methoxyphenoxy]propoxy}dimethylsilane

CH₃S0₂C1 (4.02 mL, 51.9 mmol) was added to the mixture of the product from step (ii) (8.47 g, 25.9 mmol), DIPEA (13.4 mL, 77.7 mmol) and LiCl (3.29 g, 77.7 mmol) in THF (105 mL) at r.t. and stirred for 40 mins. The mixture was diluted with water and brine, and extracted with EtOAc. The combined organic solutions were washed with brine, dried (Na₂S0₄) and concentrated to give 10.0 g of the sub-title compound as a yellow oil; Ή NMR: 7.23 (1H, dd), 6.44-6.49 (2H, m), 4.63 (2H, s), 4.06 (2H, t), 3.85 (3H, s), 3.79 (2H, t), 1.94-2.02 (2H, m), 0.89 (9H, s), 0.04 (6H, s).

(iv) Methyl 2-|4-[3-(/'grf-butyldimethylsilyloxy)propoxy]-2-methoxybenzyl}-3-oxobutanoate

Methyl acetoacetate (4.18 mL, 38.9 mmol) was added to the suspension of NaH (55% oil dispersion, 1.70 g, 38.9 mmol) in DMF (60 mL) at 0°C and stirred at r.t. for 0.5h. The product from step (iii) (10.0 g) in DMF (60 mL) and I (4.73 g, 28.5 mmol) were added to the mixture and stirred at 80°C for 6h. The mixture was cooled to r.t. and diluted with water and extracted with EtOAc. And the combined organic solutions were washed with water and brine, dried (Na₂S0₄) and concentrated. Purification by FCC, eluting with hexane / EtOAc gave 9.98 g of the sub-title compound as a yellow oil (23.5 mmol, 91% overall); Ή NMR: 6.99 (IH, d), 6.42 (1H, d), 6.37 (1 H, dd), 4.02 (2H, t), 3.89 (1H, t), 3.80 (3H, s), 3.79 (2H, t), 3.67 (3H, s), 2.99-3.14 (2H, m), 2.17 (3H, s), 1.92-2.00 (2H, m), 0.88 (9H, s), 0.04 (6H, s).

(v) 2-Ajnino-5-{4-[3-(tg^butyldimethylsilyloxy propoxy1-2-methoxyben2yl}-6- methylpyrimidin-4-ol

Guanidium carbonate (6.40 g, 35.5 mmol) was added to a solution of the product from step (iv) (1 1.6 g, 27.3 mmol) in MeOH (1 16 mL) and heated at 75°C for 8h. The mixture was cooled to r.t. and concentrated. The residue was diluted with EtOAc (50 mL) and water (50 mL), and stirred for 5.5h. The precipitate was collected and washed with water and EtOAc to afford 7.49 g (17.3 mmol, 63%) of the sub-title compound as a white solid ;1H NMR: (d⁶- DMSO) 10.75 (1H, br s), 6.71 (1H, d), 6.48 (1H, d), 6.36 (1H, dd), 6.30 (2H, br s), 3.97 (2H, t), 3.77 (3H, s), 3.73 (2H, t), 3.45 (2H, s), 1.92 (3H, s), 1.82-1.90 (2H, m), 0.85 (9H, s), 0.02 (6H, s); LC-MS: m/z = 434 [MH⁺] (T = 2.19).

(vi) 2-Amino-5-(4-[3-(?grt-butyldimethylsilyloxy propoxy1-2-methoxybenzyl)-6- methylpyrimidin-4-yl 2.4,6-trimethylbenzenesulfonate

2-Mesitylenesulfonyl chloride (4.96 g, 22.7 mmol) was added to a solution of N,NJV',N'- tetramethyl-l ,3-propanediamine (3.79 mL, 22.7 mmol) and the product from step (v) (6.55 g, 15.1 mmol) in THF (66 mL) and the mixture was stirred at r.t. for 3h. The resulting mixture was diluted with water and extracted with EtOAc. And the combined organic solutions were washed with brine, dried (Na₂S0₄) and concentrated. Purification by FCC, eluting with hexane / EtOAc gave 8.87 g (14.4 mmol, 95%) of the sub-title compound as a white solid; Ή NMR: 6.93 (2H, s), 6.71 (1H, d), 6.41 (1H, d), 6.33 (1H, dd), 4.66 (2H, br s), 4.02 (2H, t), 3.78 (3H, s), 3.77-3.82 (2H, m), 3.75 (2H, s), 2.59 (6H, s), 2.31 (3H, s), 2.25 (3H, s), 1.93- 2.01 (2H, m), 0.89 (9H, s), 0.05 (6H, s); LC-MS: m/z = 616 [MH⁺] (T = 2.99). fvii ( S)-ter t- uty\ l-hydroxyhexan-3-ylcarbamate

-^OH

BocHN^{'^} Di- err-butyl dicarbonate (2.62 g, 12.0 mmol) was added to a solution of (S)-3-aminohexan-l - ol (1.17 g, 10.0 mmol ) in 5N NaOH aq. (2.4mL, 12.0 mmol), water (2.6 mL) and 1 ,4-dioxane (lOmL) and the mixture was stirred at r.t. for 2h. The resulting mixture was diluted with water and extracted with EtOAc. And the combined organic solutions were dried (Na₂S0₄) and concentrated to give 2.39 g of the sub-title compound as yellow oil; LC-MS: m/z = 218 [MH⁺] (T = 1.97).

(viii) GS erf-Butyl l -(benzyloxy)hexan-3-ylcarbamate

-^^OBn

NaH (55% oil dispersion, 240 mg, 5.5 mmol) was added to a solution of the product from step (vii) (1.20 g, 5.0 mmol) and benzyl bromide (0.654 mL, 5.5 mmol) in DMF (20 mL) at 0°C and stirred for 2h. The resulting mixture was diluted with water and extracted with EtOAc. And the combined organic solutions were washed with water and brine, dried (Na₂S0₄) and concentrated. Purification by FCC eluting with hexane / EtOAc gave 1.16 g (3.77 mmol, 76%) of the sub-title compound as a colourless oil; LC-MS: m/z = 308 [MH⁺] (T = 2.54). fix) (S)- 1 -(Benzy loxy hexan-3 -amine

4N HCl/l ,4-dioxane (20 mL) was added to the product from step (viii) (1.16g, 3.77 mmol) and stirred at r.t. for 5h. The resulting mixture was concentrated, diluted with 40% K₂C0₃ aq. and extracted with EtOAc. The combined organic solutions were dried (Na₂S0₄) and concentrated to give 789 mg (3.77 mmol, 100%) of the sub-title compound as yellow oil; Ή NMR: 7.25-7.37 (5H, m), 4.51 (2H, s), 3.53-3.64 (2H, m), 2.86-2.94 (1H, m), 1.22-1.80 (6H, m), 0.91 (3H, t); LC-MS: m/z = 208 [MH⁺] (T = 1.66).

(x) (S)-A^r4-[l -(Benzyloxy hexan-3-yl1-5-{4-[3-(/grr-butyldimethylsilyloxy propoxy]-2- methoxybenzyl 1 -6-methylpyrimidine-2,4-diamine

Trifluoroacetic acid (98 μί, 1.27 mmol) was added to a solution of the product from step (vi) (781 mg, 1.27 mmol) and the product from step (ix) (789 mg, 3.81 mmol) at r.t. and stirred at 120°C for 15h. The resulting mixture was cooled to r.t. and concentrated. The residue was diluted with 40% K₂C0₃ aq. and extracted with CHCl₃/EtOH (3/1). The combined organic solutions were dried (Na₂S0₄) and concentrated. The residue was diluted with EtOAc, stirred, filtered, and concentrated. Purification by FCC, eluting with hexane / EtOAc gave 805 mg of the sub-title compound as yellow oil [as a mixture with the product from step (ix)]; LC-MS: m/z = 624 [MH⁺] (T = 2.48).

(xi) (iSl-3-[4-((2-Ainino-4-[l -(benzyloxy)hexan-3-ylamino]-6-methylpyrimidin-5-yl}methyl)- 3-methoxyphenoxy]propan- 1 -ol

Concentrated HC1 (12N, 529μί, 6.35 mmol) was added to a solution of the product from step (x) (805 mg, 1.27 mmol) in MeOH (10 mL) and stirred at r.t. for lh. The resulting mixture was concentrated, diluted with sat. NaHC0₃ aq. and extracted with EtOAc. The combined organic solutions were dried (Na₂S0₄) and concentrated. Purification by FCC, eluting with CHC1₃ / MeOH gave 476 mg (0.936 mmol, 74%) of the sub-title compound as yellow oil; Ή NMR: 7.21 -7.34 (5H, m), 6.79 (IH, d), 6.44 (IH, d), 6.35 (IH, dd), 4.75 (I H, d), 4.53 (2H, br s), 4.33 (2H, s), 4.20-4.31 (IH, m), 4.05 (2H, t), 3.83 (3H, s), 3.83 (2H, t), 3.57 (2H, s), 3.23- 3.34 (2H, m), 2.29 (3H, s), 1.96-2.04 (2H, m), 1.70-1.85 (IH, m), 1.45-1.58 (IH, m), 1.19- 1.45 (2H, m), 1.05-1.19 (2H, m), 0.80 (3H, t); LC-MS: m/z = 510 [MH⁺] (T = 2.02).

(xii (_lS^f)-3-[4-((2-Amino-4-[l-(benzyloxy)hexan-3-ylamino]-6-methylpyrimidin-5- yl ] methyl)-3 -methoxyphenoxyjpropyl methanesulfonate

Mesyl chloride (86 μΐ_^, 1.11 mmol) was added to a solution of the product from step (xi) (470 mg, 0.924 mmol) and triethylamine (0.258 mL, 1.85 mmol) in THF (10 mL) at 0°C and stirred for 40 mins. Mesyl chloride (215 μί, 2.78 mmol) and triethylamine (0.774 mL, 5.55 mmol) was added to the mixture at 0°C until the completion of the reaction. The resulting mixture was diluted with sat. NaHC0₃ aq. and extracted with EtOAc. The combined organic solutions were dried (Na₂S0₄) and concentrated to give 559 mg (0.924 mmol, 100%) of the sub-title compound as yellow oil; Ή NMR: 7.21-7.34 (5H, m), 6.79 (IH, d), 6.43 (IH, d), 6.33 (IH, dd), 4.75 (IH, d), 4.52 (2H, br s), 4.41 (2H, t), 4.34 (2H, s), 4.20-4.32 (IH, m), 4.01 (2H, t), 3.84 (3H, s), 3.57 (2H, s), 3.25-3.36 (2H, m), 2.97 (3H, s), 2.29 (3H, s), 2.14-2.22 (2H, m), 1.70-1.85 (IH, m), 1.46-1.58 (IH, m), 1.32-1.44 (IH, m), 1.20-1.32 (IH, m), 1.05-1.18 (2H, m), 0.79 (3H, t).

(xiii) (y)-2-{3-[4-((2-Amino-4-[l-(benzyloxyhexan-3-ylamino]-6-methylpyrimidin-5- yl I methyl -3 -methoxyphenoxy] propy lamino } ethanol

The mixture of the product from step (xii) (140 mg, 0.231 mmol) and ethanolamine (279 μί, 4.62 mmol) in CH₃CN/water (2mL/lmL) was stirred at 80°C for 6h. The resulting mixture was diluted with 40% K₂C0₃ aq. and extracted with EtOAc. The combined organic solutions were dried (Na₂S0₄) and concentrated. Purification by FCC, elu^'ting with CHC1₃ / MeOH gave 106 mg (0.192 mmol, 83%) of the sub-title compound as a colourless oil; 1H NMR:

7.21- 7.32 (5H, m), 6.77 (IH, d), 6.43 (IH, d), 6.33 (IH, dd), 4.77 (IH, d), 4.63 (2H, br s), 4.32 (2H, s), 4.19-4.32 (IH, m), 3.96 (2H, t), 3.83 (3H, s), 3.62-3.67 (2H, m), 3.56 (2H, s),

3.22- 3.34 (2H, m), 2.74-2.82 (4H, m), 2.28 (3H, s), 1.88-1.97 (2H, m), 1.73-1.84 (IH, m), 1.45-1.57 (IH, m), 1.20-1.43 (2H, m), 1.05-1.17 (2H, m), 0.79 (3H, t).

(xiv (S)-3-(2- Amino-5 - { 4- [3-(2-hydroxyethylamino)propoxy] -2-methoxybenzyl I -6- methylpyrimidin-4-ylamino)heptan- 1 -ol

5% HCl/MeOH (2 mL) was added to a solution of the product from step (xiii) (106 mg, 0.192 mmol) and 10% Pd/C (500 mg) and the mixture was stirred at r.t. for 7h under H₂. The resulting mixture was filtered and concentrated. The residue was diluted with 40% K₂C0₃ aq. and extracted with CHCl₃ EtOH (3/1). The combined organic solutions were dried (Na₂S0₄) and concentrated. Purification by FCC, eluting with CHCl₃ MeOH gave 66 mg (0.143 mmol, 74%) of the title compound as a colourless oil; 1H NMR: 6.83 (IH, d), 6.46 (IH, d), 6.38 (IH, dd), 4.54-4.65 (3H, m), 4.05-4.15 (IH, m), 4.00 (2H, t), 3.87 (3H, s), 3.60-3.68 (4H, m), 3.42- 3.50 (IH, m), 3.30 (IH, td), 2.77-2.85 (4H, m), 2.33 (3H, s), 1.90-2.02 (2H, m), 1.73-1.85 (IH, m), 1.35-1.48 (IH, m), 0.99-1.30 (4H, m), 0.77 (3H, t); LC-MS: m/z = 463 [MH⁺] (T =

1.53).

Example 2: S -3-(2-Amino-5-(2-methoxy-4-[3-(methylamiDo^")propoxylbenzyl}-6- methylpyrimidin^-ylamino^'thexan-l-ol

The title compound may be prepared by the steps described below:

(T) (5 -2-|3-[4-(|2-Amino-4-[l-(benzyloxy hexan-3-ylamino]-6-methylpyrimidin-5- yl ) methylV3-methoxyphenoxy]propylamino I ethanol

The mixture of the product from Example 1 step (xii) (140 mg, 0.231 mmol) and methylamine (9.8 M in MeOH, 1 mL) in CH₃CN/water (2mL/lmL) was stirred at 80°C for 1.5h. The resulting mixture was diluted with 40% K₂C0₃ aq. and extracted with EtOAc. The combined organic solutions were dried (Na₂S0₄) and concentrated. Purification by FCC, eluting with CHC1₃ / MeOH gave 122 mg (0.231 mmol, 100%) of the sub-title compound as a colourless oil; 1H NMR: 7.22-7.32 (5H, m), 6.78 (IH, d), 6.44 (IH, d), 6.34 (IH, dd), 4.75 (IH, d), 4.51 (2H, br s), 4.33 (2H, s), 4.20-4.32 (IH, m), 3.96 (2H, t), 3.83 (3H, s), 3.57 (2H, s), 3.24-3.35 (2H, m), 2.73 (2H, t), 2.43 (3H, s), 2.29 (3H, s), 1.88-1.98 (2H, m), 1.73-1.84 (I H, m), 1.45- 1.57 (IH, m), 1.20-1.43 (2H, m), 1.05-1.17 (2H, m), 0.79 (3H, t).

(ii) (^' _tS^f)-3-(2-Amino-5-(2-methoxy-4-[3-(methylamino propoxy]benzv -6-methylpyrimidin-

4-ylamino hexan- 1 -ol

This compound was prepared using the product from step Example 2 step (i) (122 mg, 0.231 mmol) and the method of Example 1 step (xiv) to give 79 mg (0.183 mmol, 79%) of the title compound as a colourless oil; Ή NMR: 6.81 (IH, d), 6.44 (I H, d), 6.37 (IH, dd), 4.68-4.75 (2H, m), 4.55 (IH, d), 4.02-4.14 (IH, m), 3.98 (2H, t), 3.85 (3H, s), 3.60 (2H, s), 3.40-3.48 (IH, m), 3.28 (I H, td), 2.73 (2H, t), 2.42 (3H, s), 2.31 (3H, s), 1.88-1.98 (2H, m), 1.73-1.84 (IH, m), 1.31 -1.45 (IH, m), 0.97-1.26 (4H, m), 0.74 (3H, t).

Example 3: (S)-3-(2-AmiDO-5-(2-methoxy-4-f3- piperazin-l-yl)propoxy|benzyl}-6- methylpyrimidin-4-ylamino)hex -l-ol

The title compound may be prepared by the steps described below: (i (S -A^-[l-(Benzyloxy hexan-3-yl]-5-{2-m

methylpyrimidine-2.4-diamine

The mixture of the product from Example 1 step (xii) (140 mg, 0.231 mmol) and piperazine ( 1.00 g, 1 1.6 mmol) in CH₃CN/water (3mL/3mL) was stirred at 80°C for 6h. The resulting mixture was diluted with 40% K₂C0₃ aq. and extracted with EtOAc. The combined organic solutions were dried ( a₂S0₄) and concentrated. Purification by FCC, eluting with CHC1₃ / MeOH gave 136 mg (0.231 mmol, 100%) of the sub-title compound as a colourless oil; ^JH NMR: 7.20-7.32 (5H, m), 6.76 (IH, d), 6.42 (IH, d), 6.33 (IH, dd), 4.78 (I H, d), 4.69 (2H, br s), 4.31 (2H, s), 4.19-4.30 (IH, m), 3.92 (2H, t), 3.82 (3H, s), 3.55 (2H, s), 3.21-3.33 (2H, m), 2.84-2.89 (4H, m), 2.35-2.57 (6H, m), 2.28 (3H, s), 1.87-1.96 (2H, m), 1.72-1.83 (IH, m), 1.44-1.57 (ΙΗ, πι), 1.18- 1.44 (2H, m), 1.03- 1.15 (2H, m), 0.78 (3H, t).

(ii) (S -3-(2-Amino-5-{2-methoxy-4-[3-(piperazin-l-ynpropoxy]benzyl)-6-methylpyrimidin- 4-ylamino)hexan- 1 -ol

This compound was prepared using the product from Example 3 step (i) (136 mg, 0.231 mmol) and the method of Example 1 step (xiv) to give 89 mg (0.183 mmol, 79%) of the title compound as a colourless oil; Ή NMR: 6.83 (IH, d), 6.45 (IH, d), 6.38 (I H, dd), 4.53-4.60 (3H, m), 4.02-4.15 (I H. m), 3.97 (2H, t), 3.86 (3H, s), 3.62 (2H, s), 3.42-3.51 (IH, m), 3.30 (IH, td), 2.86-2.92 (4H, m), 2.39-2.52 (6H, m), 2.33 (3H, s), 1.90-1.99 (2H, m), 1.75-1.86 (IH, m), 1.36-1.47 (IH, m), 0.98-1.28 (4H, m), 0.76 (3H, t); LC-MS: m/z = 488 [MH⁺] (T = 1.50). Example 4: (S)-3-(2-Amino-5-i4-f3-(dimethylamino)propoxyl-2-methoxybenzyl}-6- methylpyrimidin-4-ylainino hexan-l-ol

The title compound may be prepared by the steps described below:

(i) (S -A^-[l -(Berizyloxy hexan-3-yl]-5-(4- 3-(dimethylamino propoxy]-2-methoxybenzyll- 6-methylpyrimidine-2,4-diamine

The mixture of the product from Example 1 step (xii) (140 mg, 0.231 mmol) and

dimethylamine (50% in water, 1 mL) in CH₃CN (2 mL) was stirred at 80°C for 1.5h. The resulting mixture was diluted with 40% K2CO3 aq. and extracted with EtOAc. The combined organic solutions were dried (Na₂S04) and concentrated. Purification by FCC , eluting with CHCI3 / MeOH gave 1 16 mg (0.216 mmol, 94%) of the sub-title compound as a colourless oil; Ή NMR: 7.21-7.34 (5H, m), 6.78 (IH, d), 6.44 (IH, d), 6.35 (I H, dd), 4.75 (IH, d), 4.49 (2H, br s), 4.33 (2H, s), 4.20-4.32 (IH, m), 3.94 (2H, t), 3.83 (3H, s), 3.57 (2H, s), 3.25-3.32 (2H, m), 2.37-2.46 (2H, m), 2.30 (3H, s), 2.23 (6H, s), 1.87-1.96 (2H, m), 1.74-1.85 (IH, m), 1.45-1.58 (I H, m), 1.20-1.44 (2H, m), 1.05-1.18 (2H, m), 0.79 (3H, t); LC-MS: m/z = 537 [MH⁺] (T = 3.40).

(ii) (S)-3-(2-Amino-5-{4-[3-(dimethylamino)propoxy]-2-methoxybenzyl}-6- methylpyrimidin-4-ylamino hexan- 1 -ol

5% HCl/MeOH (2 mL) was added to a solution of the product from step (i) (1 16 mg, 0.216 mmol) and 10% Pd/C (500 mg) in MeOH (6 mL) and the mixture was stirred at r.t. for 3h under ¾. The resulting mixture was filtered and concentrated. The residue was diluted with 40% K₂C0₃ aq. and extracted with EtOAc. The combined organic solutions were dried

(Na₂S0₄) and concentrated. Purification by FCC, eluting with CHC1₃ / MeOH gave 84 mg (0.189 mmol, 87%) of the title compound as a colourless oil; Ή NMR: 6.81 (I H, d), 6.43- 6.47 (IH, m), 6.35-6.40 (IH, m), 4.70 (I H, br s), 4.56 (IH, d), 4.00-4.15 (IH, m), 3.95 (2H. t), 3.85 (3H, s), 3.60 (2H, s), 3.40-3.50 (IH, m), 3.24-3.35 (IH, m), 2.42 (2H, t), 2.31 (3H, s), 2.22 (6H, s), 1.87-1.96 (2H, m), 1.73-1.85 (IH, m), 1.31-1.46 (IH, m), 0.98-1.26 (4H, m), 0.75 (3H, t).

Example 5: (S)-2- 2-Amino-5-i4-f3-fdimethylamino)propoxyl-2-inethoxybenzyl}-6- methylpyrimidin-4-ylamino)pentan-l-ol

The title compound may be prepared by the steps described below:

(T) ( S)-ter f-Butyl 1 -hydroxypentan-2-ylcarbamate

^OH

BocHN

This compound was prepared using (5)-2-aminopentan-l -ol (1.0 g, 9.71 mmol) and the method of Example 1 step (vii) to give 1.73 g (8.51 mmol, 88%) of the sub-title compound as a yellow oil; LC-MS: m/z = 204 [MH⁺] (T = 1.90).

(ii) (SWe -Butyl 1 -(benzyloxy)pentan-2-ylcarbamate BocHN

This compound was prepared using the product from step (i) ( 1.62 g, 7.97 mmol) and the method of Example 1 step (viii) to give 1.83 g (6.24 mmol, 78%) of the sub-title compound as a colourless oil; LC-MS: m/z = 294 [MH⁺] (T = 2.50). f in) (S)- 1 -(Benzyloxy)pentan-2-amine

This compound was prepared using the product from step (ii) (680 mg, 2.3 1 mmol) and the method of Example 1 step (ix) to give 480 mg (2.3 1 mmol, 100%) of the sub-title compound as a yellow oil; Ή NMR: 7.28-7.38 (5H, m), 4.53 (2H, s), 3.46 ( I H, dd), 3.23 (I H, dd), 2.96- 3.04 (I H, m), 1.20- 1 .49 (4H, m), 0.91 (3H, t); LC-MS: m/z = 194 [MH⁺] (T = 1.60).

(iv) (5>A^-[ l -(Benzyloxy pentan-2-yl]-5-{4-[3-(te^

This compound was prepared using the product from Example 1 step (vi) (399 mg, 0.648 mmol) and the product from step (iii) (376 mg, 1.95 mmol) and the method of Example 1 step (x) to give 390 mg (0.641 mmol, 79%) of the sub-title compound as a yellow oil; Ή NMR: 7.20-7.34 (5H, m), 6.81 (I H, d), 6.41 (I H, d), 6.34 (I H, dd), 4.95 (I H, d), 4.51 (2H, br s), 4.39 (2H, s), 4.20-4.31 (I H, m), 3.98 (2H, t), 3.77 (3H, s), 3.75-3.79 (2H, m), 3.60 (2H, s), 3.45 (I H, dd), 3.32 ( I H, dd), 2.30 (3H, s), 1.91 -1.99 (2H, m), 1.48- 1.60 (I H, m), 1.27- 1.39 (I H, m), 1.05- 1.18 (2H, m), 0.87 (9H, s), 0.80 (3H, t), 0.03 (6H, s); LC-MS: m/z = 610 [MH⁺] (T = 2.50).

(V) (S)-3-[4-({2-Amino-4-[l -(benzyloxy pentan-2-ylamino]-6-methylpyrimidin-5-yllmethyn- 3-methoxyphenoxy]propan-l -ol

This compound was prepared using the product from step (iv) (385 mg, 0.632 mmol) and the method of Example 1 step (xi) to give 320 mg (0.632 mmol, 100%) of the sub-title compound as a yellow oil; Ή NMR: 7.18-7.34 (5H, m), 6.81(1H, d), 6.41 (IH, d), 6.34 (IH, dd), 4.93 (IH, d), 4.51 (2H, br s), 4.38 (2H, s), 4.22-4.34 (IH, m), 4.04 (2H, t), 3.84 (2H, t), 3.78 (3H, s), 3.61 (2H, s), 3.45 (IH, dd), 3.33 (IH, dd), 2.30 (3H, s), 1.97-2.04 (2H, m), 1.47-1.60 (IH, m), 1.27-1.40 (IH, m), 1.04-1.19 (2H, m), 0.81 (3H, t); LC-MS: m/z = 496 [MH⁺] (T = 2.02).

(vi) (S)-3-[4-( { 2-Amino-4- [ 1 -(benzyloxy)pentan-2-ylamino] -6-methylpyrimidin-5- yl}methyl)-3-methoxyphenoxy]propyl methanesulfonate

This compound was prepared using the product from step (v) (174 mg, 0.362 mmol) and the method of Example 1 step (xii) to give 194 mg (0.339 mmol, 96%) of the sub-title compound as a yellow oil; 1H NMR: 7.18-7.34 (5H, m), 6.82 (IH, d), 6.41 (IH, d), 6.32 (IH, dd), 4.96 (IH, d), 4.57 (2H, br s), 4.42 (2H, t), 4.39 (2H, s), 4.22-4.33 (IH, m), 4.00 (2H, t), 3.79 (3H, s), 3.61 (2H, s), 3.45 (IH, dd), 3.34 (IH, dd), 2.97 (3H, s), 2.30 (3H, s), 2.15-2.23 (2H, m), 1.48-1.60 (IH, m), 1.21-1.43 (IH, m), 1.06-1.19 (2H, m), 0.81 (3H, t); LC-MS: m/z = 573 [MH⁺] (T = 2.06). fvii) (S-A⁴-[l-(Benzyloxy)pentan-2-yll-5-{4-[3-(dimethylamino)propoxy]-2- methoxybenzyl } -6-methylpyrimidine-2.4-diamine

This compound was prepared using the product from step (vi) (194 mg, 0.339 mmol) and the method of Example 4 step (i) to give 85 mg (0.163 mmol, 48%) of the sub-title compound as a colourless oil; Ή NMR: 7.19-7.34 (5H, m), 6.80 (IH, d), 6.41 (I H, d), 6.34 (IH, dd), 4.95 (IH, d), 4.53 (2H, br s), 4.38 (2H, s), 4.21 -4.31 (IH, m), 3.93 (2H, t), 3.78 (3H, s), 3.60 (2H, s), 3.45 (IH, dd), 3.33 (IH, dd), 2.42 (2H, t), 2.30 (3H, s), 2.24 (6H, s), 1.87-1.96 (2H, m), 1.48-1.60 (IH, m), 1.27-1.40 (IH, m), 1.06-1.19 (2H, m), 0.81 (3H, t); LC-MS: m/z = 523 [MH⁺] (T = 0.58). (viii) (S -2-(2-Amino-5-{4-[3-(dimethylamino)propoxy]-2-methoxybenzyli-6- methylpyrimidin-4-ylamino pentan- 1 -ol

This compound was prepared using the product from step (vii) (85 mg, 0.163 mmol) and the method of Example 4 step (ii) to give 43 mg (0.100 mmol, 61%) of the title compound as a colourless oil; Ή NMR: 6.83 (IH, d), 6.47 (IH, d), 6.39 (IH, dd), 4.87 (I H, d), 4.61 (2H, br s), 3.91 -4.02 (IH, m), 3.97 (2H, t), 3.86 (3H, s), 3.63 (2H, s), 3.62-3.66 (IH, m), 3.41 (IH, dd), 2.43 (2H, t), 2.33 (3H, s), 2.24 (6H, s), 1.87-2.00 (2H, m), 1.35-1.47 (I H, m), 1.05-1.31 (3H, m), 0.81 (3H, t); LC-MS: m/z = 433 [MH⁺] (T = 1.54).

Example 6; (S)-2-(2-Amino-5-{2-methoxy-4-f3-(methylamino)propoxylbenzvn-6- methylpyrimidin-4-ylamino)pentan-l-ol

The title compound may be prepared by the steps described below:

(T) (^{' f})-A^/ - l-(^'Benzyloxypentan-2-yl]-5-{2-methoxy-4-[3-(methylaminopropoxy]benzyll-6- methylpyrimidine-2,4-diamine

This compound was prepared using the product from Example 5 step (vi) (100 mg, 0.158 mmol) and the method of Example 2 step (i) to give 52 mg (0.102 mmol, 65%) of the sub-title compound as a colourless oil; 1H NMR: 7.18-7.34 (5H, m), 6.80 (IH, d), 6.41 (IH, d), 6.33 (IH, dd), 4.95 (IH, d), 4.60 (2H, br s), 4.38 (2H, s), 4.22-4.32 (IH, m), 3.95 (2H, t), 3.77 (3H, s), 3.60 (2H, s), 3.44 (IH, dd), 3.33 (IH, dd), 2.74 (2H, t), 2.43 (3H, s), 2.30 (3H, s), 1.89- 1.97 (2H, m), 1.48-1.59 (IH, m), 1.25-1.40 (IH, m), 1.05-1.18 (2H, m), 0.81 (3H, t); LC-MS: m/z = 50S [MH⁺] (T = 1.78).

(ii) (.y)-2-(2-Amino-5-i2-methoxy-4-[3-(methylamino)propoxy1benzyl-6-methylpyrimidin-4- ylamino)pentan- 1 -ol

This compound was prepared using the product from step (i) (52 mg, 0.102 mmol) and the method of Example 1 step (xiv) to give 11 mg (0.0263 mmol, 26%) of the title compound as a colourless oil; Ή NMR: 6.83 (IH, d), 6.46 (IH, d), 6.38 (IH, dd), 4.87 (IH, d), 4.67 (2H, br s), 3.92-4.02 (IH, m), 3.99 (2H, t), 3.85 (3H, s), 3.62 (2H, s), 3.60-3.65 (I H, m), 3.41 (IH, dd), 2.75 (2H, t), 2.44 (3H, s), 2.32 (3H, s), 1.90-1.99 (2H, m), 1.35-1.47 (IH, m), 1.05-1.31 (3H, m), 0.81 (3H, t); LC-MS: m/z = 418 [MH⁺] (T = 1.53).

Example 7: rS)-2-(2-Amino-5-i4-[3-(2-hvdroxyethylainino)propoxyl-2-methoxybenzvn- 6-methylpyrimidin-4-ylamino)pentan-l-ol

The title compound may be prepared by the steps described below:

(i (5)-2-l3- 4-((2-Amino-4-[l-(benzyloxy)pentan-2-ylamino]-6-methylpyrimidin-5- yl 1 methvO-3-methoxyphenoxy]propylamino I ethanol

This compound was prepared using the product from Example 5 step (vi) (100 mg, 0.158 mmol) and the method of Example 1 step (xiii) to give 41 mg (0.0763 mmol, 48%) of the subtitle compound as a colourless oil; Ή NMR: 7.18-7.34 (5H, m), 6.81 (IH, d), 6.41 (I H, d), 6.33 (I H, dd), 4.94 (I H, d), 4.57 (2H, br s), 4.38 (2H, s), 4.22-4.32 (IH, m), 3.95 (2H, t), 3.78 (3H, s), 3.59-3.66 (4H, m), 3.44 (IH, dd), 3.33 (I H, dd), 2.76-2.82 (4H, m), 2.29 (3H, s), 1.89-1.98 (2H, m), 1.48-1.59 (I H, m). 1.25-1.40 (IH, m), 1.06-1.18 (2H, m), 0.81 (3H, t); LC-MS: m/z = 538 [MH⁺] (T = 1.76).

(ii ( )-2-(2-Amino-5-(4-[3-(2-hvdroxyethylamino)propoxy]-2-methoxybenzyU-6- methylpyrimidin-4-ylamino)pentan- 1 -ol

This compound was prepared using the product from step (i) (41 mg, 0.0763 mmol) and the method of Example 1 step (xiv) to give 23 mg (0.0514 mmol, 67%) of the title compound as a colourless oil; 1H NMR: 6.83 (1H, d), 6.46 (1H, d), 6.38 (1H, dd), 4.87 (1 H, d), 4.67 (2H, br s), 3.92-4.03 (1H, m), 4.01 (2H, t), 3.86 (3H, s), 3.59-3.69 (5H, m), 3.41 (1 H, dd), 2.77-2.86 (4H, m), 2.32 (3H, s), 1.90-1.99 (2H, m), 1.36-1.47 (1H, m), 1.06-1.31 (3H, m), 0.81 (3H, t).

Example 8: (S -2-(2-Amino-5-{2-methoyv-4-f3-(piperaziD-l-vnpropoxylbenzyl}-6- methylpyrimidin-4-ylamino) entan-l-oi

The mixture of the product from step Example 5 step (vi) (100 mg, 0.158 mmol) and N-tert- butoxycarbonyl-piperazine (147 mg, 0.790 mmol) in C¾CN/water (2mL/lmL) was stirred at 80 °C for 3 h. The resulting mixture was diluted with 40% K2CO3 aq. and extracted with EtOAc. The combined organic solutions were dried (Na₂S0₄) and concentrated. Purification by FCC, eluting with CHC1₃ / MeOH gave (S)-ferf-butyl 4-{3-[4-({2-amino-4-[l -

(benzyloxy)pentan-2-ylamino]-6-methylpyrimidin-5-yl}methyl)-3-methoxyphenoxy]- propyl}piperazine-l -carboxylate as a mixture with N-teri-butoxycarbonyl-piperidine and used for the next step without further purification.

5% HCl/MeOH (2 mL) was added to a solution of the resulting mixture and 10% Pd/C (300 mg) and the mixture was stirred at r.t. for 3.5 h under H₂. The resulting mixture was filtered and concentrated. 4N HCl/l ,4-dioxane (10 mL) was added to the residue and stirred for 1 h. The mixture was concentrated, diluted with 40% K2CO3 aq. and extracted with CHCl₃/EtOH (3/1). The combined organic solutions were dried (Na₂S0₄) and concentrated. Purification by FCC , eluting with CHC1₃ / MeOH gave 20 mg (0.0423 mmol, 27%) of the title compound as a colourless oil; Ή NMR: 6.83 (I H, d), 6.45 (IH, d), 6.38 (I H, dd), 4.88 (I H, d), 4.71 (2H, br s), 3.93-4.03 (I H, m), 3.96 (2H, t), 3.85 (3H, s), 3.62 (2H, s), 3.60-3.64 (IH, m), 3.41 (IH, dd), 2.85-2.91 (4H, m), 2.83 (2H, s), 2.36-2.53 (6H, m), 2.32 (3H, s), 1.90-1.99 (2H, m), 1.36- 1.47 (IH, m), 1.05-1.32 (3H, m), 0.80 (3H, t); LC-MS: m/z = 474 [MH⁺] (T = 1.42).

Example 9: (3S)-3-f(2-Amino-5-i4-[2-fdimethylamino)ethoxyl-2-inethoxybeDzyl)-6- methylpyrimidin-4-vDaminolhexan-l-ol

The title compound may be prepared by the steps described below:

(i Methyl 2-[4-(benzyloxy -2-methoxybenzyl]-3-oxobutanoate

DMF (7 mL) was added to a mixture of Pd-1 18) (dichloro [Ι ,Γ bis(di-/er/- butylphosphino)] ferrocene palladium (II)) (73 mg) and tetrabutyl-ammonium chloride hydrate

(264 mg) and 4-(benzyloxy)-l-bromo-2-methoxy benzene (1.31 g), under N₂. Methyl 3- hydroxy-2-methylenebutyrate (543 μί) and N-cyclohexyl-N-methylcyclohexanamine (2.84 mL) were added and the solution was heated at 100°C for 18h and then allowed to cool to RT. The mixture was diluted with CH₃OH and loaded on to a SCX cartridge. The compound was eluted with CH₃OH and the filtrate concentrated in vacuo. Purification by FCC eluting with 0- 10% EtOAc in isohexane gave the sub-title compound (888 mg) as a yellow oil; Ή NMR: 7.43 (d, 2H), 7.39 (t, 2H), 7.35-7.31 (m, IH), 7.01 (d, IH), 6.52 (d, IH), 6.45 (dd, IH), 5.03 (s, 2H), 3.89 (t, IH), 3.79 (s, 3H), 3.69 (s, 3H), 3.15-3.00 (m, 2H), 2.18 (s, 3H); LC-MS m/z 341 APCI-.

(ii) 2-Amino-5-[4-(benzyloxy -2-methoxybenzyl]-6-methylpyrimidin-4-ol

Methyl 2-[4-(benzyloxy)-2-methoxybenzyl]-3-oxobutanoate (870 mg) was dissolved in CH₃OH (14 mL) and guanidine hemicarbonate (687 mg) was added. The mixture was then heated to 60°C for 5h and allowed to cool to RT. The mixture was then filtered and washed with diethyl ether and water. The filtrate was concentrated in vacuo and more diethyl ether and water added. After scratching the crude material the resulting solid was collected by filtration, washed with water and dried under vacuum to give the sub-title compound (467 mg) as a pale yellow solid; Ή NMR: 7.44 (d, 2H), 7.39 (t, 2H), 7.32 (t, I H), 6.73 (d, IH), 6.60 (d, I H), 6.46 (dd, I H), 6.35 (s, IH), 5.05 (s, 2H), 3.77 (s, 3H), 3.45 (s, 2H), 1.93 (s, 3H); LC-MS m/z 352 APCI+.

(iii 2-Amino-5-[4-(benzyloxy -2-methoxybenzyl]-6-methylpyrimidin-4-yl 2,4,6- triisopropylbenzenesulfonate

A mixture of 2-amino-5-[4-(benzyloxy)-2-methoxybenzyl]-6-methylpyrimidin-4-ol (467 mg), 2,4,6-triisopropylbenzene-l -sulfonyl chloride (523 mg) and DABCO (194 mg) in THF (13 mL) was heated at 50°C for 3h and then allowed to cool to RT. The mixture was partitioned between EtOAc (100 mL) and water (50 mL) and the phases were separated. The organic solution was washed with further water (50 mL), sat. NaHC0₃ (2 x 50 mL) and brine (50 mL). The solution was then dried (MgS0₄) and concentrated in vacuo to give the sub-title compound (807 mg) as a yellow solid; Ή NMR: 7.43 (d, 2H), 7.39 (t, 2H), 7.32 (dd, I H), 7.16 (s, 2H), 6.78 (d, IH), 6.50 (d, IH), 6.41 (dd, IH), 5.02 (s, 2H), 4.67 (s, 2H), 4.19-4.09 (m, 2H), 3.76 (s, 5H), 2.97-2.86 (m, IH), 2.27 (s, 3H), 1.25 (d, 6H), 1.20 (d, 12H); LC-MS m/z 618 APCI+.

(iv) (3>S 3-({2-Ainino-5-[4-(benzyloxy)-2-methoxyber^

hexan-l -ol

A mixture of 2-amino-5-[4-(benzyloxy)-2-methoxybenzyl]-6-methylpyrimidin-4-yl 2,4,6- triisopropylbenzenesulfonate (807 mg, 1.31mmol), (5)-3-aminohexan-l-ol (459 mg, 3.92 mmol) and trifluoroacetic acid (0.101 mL, 1.31 mmol) in butyronitrile(7 mL) was heated at 120°C for 20 h. The mixture was then concentrated in vacuo. The crude material was purified by HPLC using a Gemini-NX CI 8 5μπι 1 1 OA 30x100 AXIA column and eluting with a gradient of 29-64% MeCN in water (containing 0.1% NH₃). Appropriate fractions were concentrated in vacuo to provide the sub-title compound (31 1 mg, 53 %) as a yellow foam;

1H NMR: 7.43-7.36 (m, 4H), 7.35-7.30 (m, IH), 6.85 (d, IH), 6.55 (d, IH), 6.47 (dd, IH), 5.13 (s, IH), 5.03 (s, 2H), 4.55 (d, 3H), 4.15-4.04 (m, IH), 3.86 (s, 3H), 3.63 (s, 2H), 3.48 (s, IH), 3.31 (t, IH), 2.34 (s, 3H), 1.86-1.75 (m, IH), 1.46-1.36 (m, IH), 1.27-1.17 (m, IH), 1.16-0.99 (m, 3H), 0.77 (t, 3H); LC-MS m/∑A5 \ APCI+.

(v) 5-[4-(Benzyloxy -2-methoxybenzyl]-A^,4-[(3S)-l -i [½rr-butyl(^'dimethyl)silyl]oxy}hexan-3- yl]-6-methylpyrimidine-2.4-diamine

Imidazole (94 mg) was added to a solution of (3S)-3-( {2-amino-5-[4-(benzyloxy)-2- methoxybenzyl]-6-methylpyrimidin-4-yl}amino)-hexan-l -ol (310 mg) and rr-butyl- dimethylsilyl chloride (207 mg) in DMF (2.5 mL) under an atmosphere of N₂, and the mixture was stirred 24h. Further terr-butyldimethylsilyl chloride (104 mg) and imidazole (47 mg) were then added and the mixture was stirred for a further 3h. The solvent was removed in vacuo and the residue was dissolved in CH2CI2 (50 mL) and the resulting solution was washed with water (4 ^χ 50 mL), dried (Na₂S0₄) and concentrated in vacuo to give the sub-title compound (506 mg) as a yellow oil; LC-MS m/z 565 APCI+.

(vi) 4-[(2-Amino-4- { [(3S)- 1 - { [/grf-butyl(dimethyOsilyl]oxy } hexan-3-yl]amino) -6-methyl- pyrimidin-5-yl methyl]-3-methoxyphenol

A mixture of 5-[4-(benzyloxy)-2-methoxybenzyl]-A^-[(35)- l -{ [/ert-butyl(dimethyl)silyl]- oxy}hexan-3-yl]-6-methylpyrimidine-2,4-diamine (390 mg) and palladium on carbon (147 mg) in EtOH (7 mL) was reacted with H₂ (3 bar) for 4h. The mixture was filtered and washed with EtOH and a solution of 10% EtOH in CH₂C1₂ and the filtrate was concentrated in vacuo. The resulting foam was scratched and treated with isohexane to give an off-white solid which was filtered, washed with further isohexane and dried under vacuum to give the sub-title compound (295 mg) as an off-white solid; 1H NMR: 6.70 (d, I H), 6.43 (d, I H), 6.16 (dd, I H), 4.87 (s, I H), 4.57 (s, 2H), 4.25-4.16 (m, I H), 3.86 (s, 3H), 3.57 (s, 2H), 3.53-3.43 (m, 2H), 2.31 (s, 3H), 1.74- 1.64 (m, 1 H), 1.54- 1.38 (m, 2H), 1.30- 1 .20 (m, 1 H), 1.08 (ddd, 2H), 0.85 (s, 9H), 0.79 (t, 3H), -0.04 (s, 6H); LC-MS m/z 475 APCI+.

(vii (3S -3-[(2-Amino-5-|4-[2-(dimethylarnino)ethoxy1-2-methoxybenzyl }-6- methylpyrimidin-4-yl amino]hexan- 1 -ol

Diisopropyl azodicarboxylate ( 1 17 iL) was added to 4-[(2-amino-4-{ [(3S)- l -{ [½rr- bu1yl(dimethyl)silyl]oxy}hexan-3-yl]amino}-6-methyl-pyrimidin-5-yl)methyl]-3- methoxyphenol (94 mg), 2-(dimethylamino)ethanol (99

and triphenylphosphine ( 156 mg) in THF (2 mL) under N₂ at 0°C. The mixture was then warmed to 60°C for 1 Oh and then further triphenylphosphine ( 156 mg), 2-(dimethylamino)ethanol (99 ih) and diisopropyl azodicarboxylate ( 1 17 iL) were added and the mixture heated at 60°C for another 2h. The mixture was then allowed to cool to RT and then poured onto an SCX cartridge. The mixture was eluted first with CH₃OH and then 1 M NH₃ in CH₃OH and the basic fraction collected and concentrated in vacuo. The resulting residue was purified by RPHPLC to give the sub-title compound (53 mg) as a colourless gum; 1H NMR: 6.65 (d, 1H), 6.54 (d, 1H), 6.40 (dd, 1H), 5.67 (s, 2H), 5.50 (d, 1 H), 4.40 (t, 1 H), 4.18 (dt, 1 H), 3.99 (t, 2H), 3.83 (s, 3H), 3.53 (s, 2H), 3.39-3.25 (m, 2H), 2.61 -2.55 (m, 2H), 2.19 (s, 6H), 2.02 (s, 3H), 1.58 (td, 1 H), 1 .47- 1.30 (m, 3H), 1.16- 1.02 (m, 2H), 0.77 (t, 3H); LC-MS m/z 432 multimode+.

Biological Assays

The ability of compounds to activate TLR7 in vitro was assessed using the human TLR7 assay described below. Human TLR7 assay

Recombinant human TLR7 was stably expressed in a HEK293 cell line already stably expressing the pNiFty2-SEAP reporter plasmid; integration of the reporter gene was maintained by selection with the antibiotic zeocin. The most common variant sequence of human TLR7 (represented by the EMBL sequence AF240467) was cloned into the

mammalian cell expression vector pUNO and transfected into this reporter cell-line. Transfectants with stable expression were selected using the antibiotic blasticidin. In this reporter cell-line, expression of secreted alkaline phosphatase (SEAP) is controlled by an NF- KB/ELAM-1 composite promoter comprising five NF-κΒ sites combined with the proximal ELAM-1 promoter. TLR signaling leads to the translocation of NF-κΒ and activation of the promoter results in expression of the SEAP gene. TLR7-specific activation was assessed by determining the level of SEAP produced following overnight incubation of the cells at 37°C with the standard compound in the presence of 0.1% (v/v) dimethylsulfoxide (DMSO).

Concentration dependent induction of SEAP production by compounds was expressed as the concentration of compound which produced half of the maximal level of SEAP induction for that compound (EC50). TLR7 activity for compounds of the present invention was assessed using the human TLR7 assay and the results are shown in Table 1 below wherein the degree of TLR7 activation for each compound is expressed as a pEC₅₀ value.

Table 1

Human TLR8 assay

TLR8/NF-KB/SEAPorter™ HEK 293 Cell Line (Imgenex Corporation) is a stably co- transfected cell line which expresses full-length human TLR8 and the secreted alkaline phosphatase (SEAP) reporter gene under the transcriptional control of an NF-κΒ response element. TLR8 expression in this cell line has been tested by flow cytometry. Transfectants with stable expression were selected using the antibiotic blasticidin and geneticin. TLR signaling leads to the translocation of NF-κΒ and activation of the promoter results in expression of the SEAP gene. TLR8-specific activation was assessed by determining the level of SEAP produced following overnight incubation of the cells at 37°C with the standard compound in the presence of 0.1% (v/v) dimethylsulfoxide (DMSO). Concentration dependent induction of SEAP production by compounds was expressed as the concentration of compound which produced half of the maximal level of SEAP induction for that compound (EC50). TLR8 activity for compounds of the present invention was assessed using the human TLR8 assay and the results are shown in Table 2 below wherein the degree of TLR8 activation for each compound is expressed as a pECso value.

Table 2

hERG ( human ether-a-go-go ) Analysis - Method 1

The hERG potassium current is measured in a hERG-stably-expressing Chinese hamster ovary l (CHO) cells. The experiments were performed using an automated planar patch-clamp system QPatch HT (Sophion Bioscience A/S). The application of pressure for forming gigaseals and whole-cell patch clamp configuration were established using the QPatch assay software. Patch-clamp experiments were performed in voltage-clamp mode and whole-cell currents were recorded from individual cells. The following stimulation protocol was applied to investigate the effects of compounds on hERG potassium channel. : The membrane potential was held at -80 mV and repetitively (every 15 s) depolarized to +20 mV for 5 s after the pulse to -50 mV for 20 ms served to define the baseline, followed by repolarizing step to -50 mV for 5 s to evaluate of the tail current amplitude. Experiments were conducted at room temperature (22±2°C).

Effects of compounds were determined from cumulative applications of increasing 4 concentrations and calculated as percent of blocked current. The data points were fitted with Hill equation to calculate half-maximal inhibition concentrations.

The test solution includes:

Extracellular solution (mM): 2mM of CaCl₂, lmM of MgCl₂, l OmM of HEPES, 4mM of KC1, 145 mM of NaCl, and l OmM of glucose; and

Intracellular solution (mM): 5.4mM of CaCl₂, 1.8mM of MgCl₂, lOmM of HEPES, 31mM of KOH, l OmM of EGTA. 120mM of KCL and 4mM of ATP.

The results are shown in Table 3, below. hERG Analysis - Method 2

Cell culture

The hERG-expressing Chinese hamster ovary Kl (CHO) cells described by (Persson,

Carlsson, Duker, & Jacobson, 2005) are grown to semi-confluence at 37°C in a humidified environment (5% C0₂) in F-12 Ham medium containing L-glutamine, 10% foetal calf serum (FCS) and 0.6mg/mL hygromycin (all available from Sigma-Aldrich). Prior to use, the monolayer is washed using a pre-warmed (37°C) 3mL aliquot of Versene 1 :5,000 (Invitrogen). After aspiration of this solution the flask is incubated at 37°C in an incubator with a further 2mL of Versene 1 :5,000 for a period of 6 mins. Cells are then detached from the bottom of the flask by gentle tapping and lOmL of Dulbecco's Phosphate-Buffered Saline containing calcium (0.9mM) and magnesium (0.5mM) (PBS; Invitrogen) is then added to the flask and aspirated into a 15mL centrifuge tube prior to centrifugation (50g, for 4 mins). The resulting supernatant is discarded and the pellet gently re-suspended in 3mL of PBS. A 0.5mL aliquot of cell suspension is removed and the number of viable cells (based on trypan blue exclusion) is determined in an automated reader (Cedex; Innovatis) so that the cell re-suspension volume can be adjusted with PBS to give the desired final cell concentration. It is the cell

concentration at this point in the assay that is quoted when referring to this parameter, CHO- vl .5 cells, which are used to adjust the voltage offset on Ion Works™ HT, are maintained and prepared for use in the same way.

Electrophysiology

The principles and operation of this device have been described by (Schroeder, Neagle, Trezise, & Worley, 2003). Briefly, the technology is based on a 384-well plate (PatchPlate™) in which a recording is attempted in each well by using suction to position and hold a cell on a small hole separating two isolated fluid chambers. Once sealing has taken place, the solution on the underside of the PatchPlate™ is changed to one containing amphotericin B. This permeablises the patch of cell membrane covering the hole in each well and, in effect, allows a perforated, whole-cell patch clamp recording to be made.

A β-test IonWorks™ HT from Essen Instrument was used. There is no capability to warm solutions in this device hence it is operated at ~r.t. (-21 °C), as follows. The reservoir in the "Buffer" position is loaded with 4 mL of PBS and that in the "Cells" position with the CHO- hERG cell suspension described above. A 96-well plate (V-bottom, Greiner Bio-one) containing the compounds to be tested (at 3-fold above their final test concentration) is placed in the "Plate 1" position and a PatchPlate™ is clamped into the PatchPlate™ station. Each compound plate is laid-out in 12 columns to enable ten, 8-point concentration-effect curves to be constructed; the remaining two columns on the plate are taken up with vehicle (final concentration 0.33% DMSO), to define the assay baseline, and a supra-maximal blocking concentration of cisapride (final concentration 10 μΜ) to define the 100% inhibition level. The fluidics-head (F-Head) of Ion Works™ HT then adds 3.5μί of PBS to each well of the PatchPlate™ and its underside is perfused with "internal" solution that had the following composition (in mM): -Gluconate (100 parts), KC1 (40 parts), MgCl₂ (3.2 parts), EGTA(3 parts) and HEPES (5 parts, pH 7.25-7.30 using 10M OH). After priming and de-bubbling, the electronics-head (E-head) then moves round the PatchPlate™ performing a hole test (i.e. applying a voltage pulse to determine whether the hole in each well is open). The F-head then dispenses 3.5μΙ, of the cell suspension described above into each well of the PatchPlate™ and the cells are given 200 seconds to reach and seal to the hole in each well. Following this, the E-head moves round the PatchPlate™ to determine the seal resistance obtained in each well. Next, the solution on the underside of the PatchPlate™ is changed to "access" solution that has the following composition (in mM): KG (140 parts), EGTA (1 part), MgCl₂ (1 part) and HEPES (20 parts, pH 7.25-7.30 using 10M KOH) plus 100μg/mL of amphotericin B (Sigma- Aldrich). After allowing 9 mins for patch perforation to take place, the E-head moves round the PatchPlate™ 48 wells at a time to obtain pre-compound hERG current measurements. The F-head then adds 3.5μΕ of solution from each well of the compound plate to 4 wells on the PatchPlate™ (the final DMSO concentration is 0.33% in every well). This is achieved by moving from the most dilute to the most concentrated well of the compound plate to minimise the impact of any compound carry-over. After approximately 3.5 mins incubation, the E-head then moves around all 384-wells of the PatchPlate™ to obtain post-compound hERG current measurements. In this way, non-cumulative concentration-effect curves can be produced where, providing the acceptance criteria are achieved in a sufficient percentage of wells (see below), the effect of each concentration of test compound is based on recording from between 1 and 4 cells.

The pre- and post-compound hERG current is evoked by a single voltage pulse consisting of a 20 second period holding at -70mV, a 160millisecond step to -60mV (to obtain an estimate of leak), a 1 OOmillisecond step back to -70mV, a 1 second step to + 40mV, a 2 second step to - 30mV and finally a 500 millisecond step to -70mV. In between the pre- and post-compound voltage pulses there is no clamping of the membrane potential. Currents are leak-subtracted based on the estimate of current evoked during the +10mV step at the start of the voltage pulse protocol. Any voltage offsets in Ion Works™ HT were adjusted in one of two ways. When determining compound potency, a depolarising voltage ramp is applied to CHO-Kvl .5 cells and the voltage noted at which there was an inflection point in the current trace (i.e. the point at which channel activation is seen with a ramp protocol). The voltage at which this occurred has previously been determined using the same voltage command in conventional electrophysiology and found to be -15mV (data not shown); thus an offset potential could be entered into the Ion Works™ HT software using this value as a reference point. When determining the basic electrophysiological properties of hERG, any offset is adjusted by determining the hERG tail current reversal potential in Ion Works™ HT, comparing it with that found in conventional electrophysiology (-82mV) and then making the necessary offset adjustment in the Ion Works™ HT software. The current signal is sampled at 2.5kHz.

Pre- and post-scan hERG current magnitude was measured automatically from the leak subtracted traces by the Ion Works™ HT software by taking a 40ms average of the current during the initial holding period at -70 mV (baseline current) and subtracting this from the peak of the tail current response. The acceptance criteria for the currents evoked in each well are: pre-scan seal resistance >60ΜΩ, pre-scan hERG tail current amplitude >150pA; post- scan seal resistance >60ΜΩ. The degree of inhibition of the hERG current can be assessed by dividing the post-scan hERG current by the respective pre-scan hERG current for each well. References: Persson, F. et al, J Cardiovasc.ElectrophysioL, 16, 329-341 (2005), and

Schroeder, K., et al, J Biomol Screen., 8, 50-64, (2003).

Table 3

As also shown in Table 3, the compounds of the invention exhibit favourable hERG inhibition activity.

Claims

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:

wherein:

n is 1, 2 or 3;

m is 1 or 2;

p is 1 or 2;

R is C_1-4alkyl or hydroxy C2_-4alkyl and R is hydrogen or C_1-4alkyl;

or R¹ and R² together with the nitrogen to which they are attached form piperazin-l-yl optionally substituted by C_1-3alkyl, or pyrrolidih-l-yl.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 2.

3. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein p is 1.

4. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.

5. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein n is 2.

6. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or methyl.

7. A compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R¹ is methyl or 2 -hydroxy ethyl.

8. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R and R together with the nitrogen to which they are attached form piperazin-l-yl or pyrrolidin-l-yl.

9. A compound according to claim 1 selected from the following, or a pharmaceutically acceptable salt thereof:

(S)-3-(2- Amino-5 - { 4- [3 -(2-hydroxyethylamino)propoxy] -2-methoxybenzyl } -6- methylpyrimidin-4-ylamino)hexan- 1 -ol;

(S)-3-(2-Amino-5-{2-methoxy-4-[3-(methylamino)propoxy]benzyl}-6- methylpyrimidin-4-ylamino)hexan- 1 -ol;

(5)-3-(2-Amino-5-{2-methoxy-4-[3-(piperazin-l -yl)propoxy]ben2:yl}-6- methylpyrimidin-4-ylamino)hexan-l-ol;

(5)-3 -(2-Amino-5- {4- [3 -(dimethylamino)propoxy] -2-methoxybenzyl } -6- methylpyrimidin-4-ylamino)hexan- 1 -ol;

(5 -2-(2- Amino-5 - { 4- [3 -(dimethylamino)propoxy] -2-methoxybenzyl } -6- methylpyrimidin-4-ylamino)pentan- 1 -ol;

(S)-2-(2-Amino-5-{2-methoxy-4-[3-(methylamino)propoxy]benzyl}-6- methylpyrimidin-4-ylamino)pentan- 1 -ol;

(5)-2-(2-Amino-5-{4-[3-(2-hydroxyethylamino)propoxy]-2-methoxybenzyl}-6- methylpyrimidin-4-ylamino)pentan-l-ol; and

(S)-2-(2-Amino-5-{2-methoxy-4-[3-(piperazin-l -yl)propoxy]benzyl}-6- methy lpyrimidin-4-ylamino)pentan- 1 -ol .

10. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, in association with a

pharmaceutically acceptable diluent or carrier.

1 1. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use as a medicament.

12. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

13. Use of a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer.

14. A method of treating cancer in a warm blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 9.